According to related industries, Takeda Pharmaceutical Korea's Livtencity submitted a benefit application in the third quarter of last year, has completed PE, and is currently submitting it to the HIRA Pharmaceutical Reimbursement Evaluation Committee. Accordingly, it remains to be seen whether an alternative treatment option can be developed for patients resistant to existing drugs.

CMV is a type of herpes virus that infects more than 60% of adults worldwide at least once in their lives. It is a typical disease that occurs in patients who use immunosuppressants after hematopoietic stem cell (HSCT) transplantation. The risk is such that 30-70% of hematopoietic stem cell transplant patients experience C